1. SCHÖLMERICH J, R STRAUB. Mechanisms of bile salt toxicity. In: Lentze M,J Reichen (Hrsg.): Paediatric cholestasis: Novel approaches to treatment. Kluwer Academic Publ., Lancaster 1992:83 - 103.

2. PATEL T, BRONIK SF, GORES GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest 1994;94:2183-2192.

3. PEDERSEN OM, NORDGARD K, KVINNSLAND S.Value of sonography in obstructive jaundice: Limitations of bile duct caliber as an index of obstruction. Scand J Gastroenterol 1987;22:975-981.

4. BALISTRERI WF. Bile acid therapy in pediatric hepatobiliary disease:The role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997;24:573-589.

5. MITCHINSON HC, LUCEY MR, KEILLY PJ, NEUBERGER JM, WILLIAMS R, JAMES OFW. Symptom development and prognosis in primary biliary cirrhosis: A study in two centers. Gastroenterology 1990;99:778-784.

6. BEUERS U, JL BOYER, G PAUMGARTNER. Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications. Hepatology 1998;28:14491453.

7. SCHÖLMERICH J, U BAUMGARTNER, K MIYAI, W GEROK. Tauroursodeoxycholate prevents taurolithocholate induced cholestasis and toxicity in rat liver. J Hepatol 11990;10:280 - 283.

8. RODRIGUES CMP, GS FAN, XM MA, BT KREN, CJ STEER. A novel role for usodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998:101:2790-2799.

9. JAZRAWI RP, JS DE CAESTECKER, PM GOGGIN, AJ BRITTEN, AEA JOSEPH, JD MAXWELL, TC NORTHFIELD. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid. Gastroenterology 1994;106:1134-142.

10. POUPON RE, R POUPON, B BALKAU, the UDCA-PBC Study Group. Ursodiol for the longterm treatment of primary biliary cirrhosis. New Engl J Med 1994;330:1342-1346.

11. HEATHCOTE EJ, K CAUCH-DUDEK, V WALKER, RJ BAILEY, LM BLENDIS, CN CHENT, P MICHIELETTI, GY MINUK, SC PAPPAS, LJ SCULLY, UP STEINBRECHER, LR SUTHERLAND, CN WILLIAMS, H WITT-SULLIVAN, LJ WOROBETZ, RA MILNER, IR WANLESS. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-1156.

12. LINDOR KD, ER DICKSON, WP BALDUS, RA JORGENSEN, J LUDWIG, PA MURTAUGH, JM HARRISON, RH WIESNER, ML ANDERSON, SM LANGE, G LESAGE, SS ROSSI, AF HOFMANN. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.

13. LINDOR KD, TM THERNEAU, RA JORGENSEN, M MALINCHOC, ER DICKSON. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110:1515-1518.

14. POUPON RE, KD LINDOR, K CAUCH-DUDEK, ER DICKSON, R POUPON, EJ HEATHCOTE. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.

15. COMBES B. Ursodeoxycholic acid in primary biliary cirrhosis. Semin Liv Dis 1997;17:125-1128.

16. LINDOR KD, RA JORGENSEN, R.N., TM THERNEAU, M MALINCHOC, ER DICKSON. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997;72:1137-1140.

17. PASHA T, J HEATHCOTE, S GABRIEL, K CAUCH-DUDEK, R JORGENSEN, T THERNEAU, ER DICKSON, KD LINDOR. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999;29:21-26.

18. WOLFHAGEN FHJ, HJF VAN HOOGSTRATEN, HR VAN BUUREN, GP VAN BERGE-HENEGOUWEN, FJW TEN KATE, WCJ HOP, EW VAN DER HOEK, MJ KERBERT, HH VAN LIJF, JW DEN OUDEN, AM SMIT, RA DE VRIES, RAA VAN ZANTEN, SW SCHALM. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1 year randomized, placebo-controlled study. J Hepatol 1998;29:736-742.

19. POUPON R, O GORIA, O CHAZOUILLÉRES, Y CHIRÉTIEN, A-M BONNAND, RE POUPON. Glucorticoids in combination with ursodeoxycholic acid (UDCA) for primary biliary cirrhosis resistant to UDCA alone. Hepatology 1997;26:400A.

20. GONZÁLES-KOCH A, J BRAHM, C ANTEZANA, G SMOK, MA CUMSILLE. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997;27:143-149.

21. LINDOR KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691695.

22. VAN HOOGSTRATEN HJF, FHJ WOLFHAGEN, PC VAN DE MEEBERG, H KUIPER, GAJJ NIX, MCJM BECX, AC HOEK, DPF VAN HOUTE, MCM RIJK, JMJI SALEMANS, J SCHERPENISSE, M SCHRIJVER, AM SMIT, P SPOELSTRA, PHGM STADHOUDERS, TG TAN, WCJ HOP, FJW TEN KATE, GP VAN BERGE-HENEGOUWEN, SW SCHALM, HR VAN BUUREN. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: result of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998;29:417-423.

23. STIEHL A, G RUDOLPH, P SAUER, C BENZ, W STREMMEL, S WALKER, L THEILMANN. Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. J Hepatol 1997;26:560-566.

24. GOODMAN ZD, MCNALLY PR, DAVIS DR, ISHAK KG.Autoimmune cholangitis: avariant of prirnary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig Dis Sci 1995;40:1232-1234.

25. SCHÖLMERICH J, M-S BECHER, K SCHMIDT, R SCHUBERT, B KREMER, S FELDHAUS, W GEROK. Influence of hydroxylation and conjugation of bile salts on their membranedamaging properties - studies on isolated hepatocytes and lipid membrane vesicles. Hepatology 1984;4:661 - 666.

26. SHERLOCK S, DOOLEY J. Diseases of the liver and biliary system. Blackweil Scientific Publications, Oxford, pp:215,231.

27. POUPON R, CHRETIEN Y, POUPON RE, BALLET F, CALMUS Y, DARNIS F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1:834-836.